Literature DB >> 20332268

Limitations of direct immunoassays for measuring circulating estradiol levels in postmenopausal women and men in epidemiologic studies.

Frank Z Stanczyk1, Jordan Jurow, Ann W Hsing.   

Abstract

Serum estradiol (E(2)) serves as an important diagnostic marker in a variety of clinical conditions. In epidemiologic studies, E(2) is commonly used to define the etiologic role of estrogen in hormone-related cancers and chronic conditions. Having an accurate and reliable E(2) assay is of critical importance in these studies, especially when measuring the very low E(2) levels (<30 pg/mL) common in postmenopausal women and men, and for discerning the relatively small (usually <20%) case-control differences in E(2) levels. Because E(2) is metabolized to >100 metabolites in the body, some of which cross-react with E(2) antibodies, direct RIAs without purification steps lack specificity for E(2) and can substantially overestimate E(2) levels. Although direct E(2) RIAs using commercial kits are simpler, less time consuming, and less expensive and require less sample volume than conventional RIAs with preceding purification steps, their lack of sensitivity and specificity makes them invalid for measuring circulating E(2) levels in epidemiologic studies of postmenopausal women or men. Instead, we recommend the use of a well-validated RIA with purification steps to improve sensitivity and specificity and to help achieve the necessary accuracy and reliability needed for epidemiologic studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332268     DOI: 10.1158/1055-9965.EPI-10-0081

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  32 in total

1.  Measuring Estrogen Exposure and Metabolism: Workshop Recommendations on Clinical Issues.

Authors:  L M Demers; S E Hankinson; S Haymond; T Key; W Rosner; R J Santen; F Z Stanczyk; H W Vesper; R G Ziegler
Journal:  J Clin Endocrinol Metab       Date:  2015-04-07       Impact factor: 5.958

2.  Biospecimens and biorepositories: from afterthought to science.

Authors:  Jimmie B Vaught; Marianne K Henderson; Carolyn C Compton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02       Impact factor: 4.254

3.  Relative hyperestrogenism in Klinefelter Syndrome: results from a meta-analysis.

Authors:  Daniele Santi; Sara De Vincentis; Sara Scaltriti; Vincenzo Rochira
Journal:  Endocrine       Date:  2019-01-30       Impact factor: 3.633

Review 4.  Metabolic pathways in obesity-related breast cancer.

Authors:  Kristy A Brown
Journal:  Nat Rev Endocrinol       Date:  2021-04-29       Impact factor: 43.330

5.  Serum Sex Hormones and the Risk of Fracture Across the Menopausal Transition: Study of Women's Health Across the Nation.

Authors:  Jane A Cauley; Kristine Ruppert; Yinjuan Lian; Joel S Finkelstein; Carrie A Karvonen-Gutierrez; Sioban D Harlow; Joan C Lo; Sherri-Ann M Burnett-Bowie; Arun Karlamangla; Gail A Greendale
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

6.  Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.

Authors:  Nanette Santoro; Amanda Allshouse; Genevieve Neal-Perry; Lubna Pal; Rogerio A Lobo; Frederick Naftolin; Dennis M Black; Eliot A Brinton; Matthew J Budoff; Marcelle I Cedars; N Maritza Dowling; Mary Dunn; Carey E Gleason; Howard N Hodis; Barbara Isaac; Maureen Magnani; JoAnn E Manson; Virginia M Miller; Hugh S Taylor; Whitney Wharton; Erin Wolff; Viola Zepeda; S Mitchell Harman
Journal:  Menopause       Date:  2017-03       Impact factor: 2.953

7.  Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.

Authors:  Sibylle Loibl; Nicholas C Turner; Jungsil Ro; Massimo Cristofanilli; Hiroji Iwata; Seock-Ah Im; Norikazu Masuda; Sherene Loi; Fabrice André; Nadia Harbeck; Sunil Verma; Elizabeth Folkerd; Kathy Puyana Theall; Justin Hoffman; Ke Zhang; Cynthia Huang Bartlett; Mitchell Dowsett
Journal:  Oncologist       Date:  2017-06-26

8.  Sex hormone levels and risk of breast cancer with estrogen plus progestin.

Authors:  Ghada N Farhat; Neeta Parimi; Rowan T Chlebowski; Joann E Manson; Garnet Anderson; Alison J Huang; Eric Vittinghoff; Jennifer S Lee; Andrea Z Lacroix; Jane A Cauley; Rebecca Jackson; Deborah Grady; Dorothy S Lane; Lawrence Phillips; Michael S Simon; Steven R Cummings
Journal:  J Natl Cancer Inst       Date:  2013-09-16       Impact factor: 13.506

9.  Serum factors and clinical characteristics associated with serum E-screen activity.

Authors:  Jue Wang; Amy Trentham-Dietz; Jocelyn D C Hemming; Curtis J Hedman; Brian L Sprague
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-15       Impact factor: 4.254

10.  Serum sex steroid levels and longitudinal changes in bone density in relation to the final menstrual period.

Authors:  Carolyn J Crandall; Chi-Hong Tseng; Arun S Karlamangla; Joel S Finkelstein; John F Randolph; Rebecca C Thurston; Mei-Hua Huang; Huiyong Zheng; Gail A Greendale
Journal:  J Clin Endocrinol Metab       Date:  2013-02-26       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.